Regenxbio Inc
RGNX
查看詳細走勢圖
14.160USD
-0.300-2.07%
收盤 12/26, 16:00（美東）報價延遲15分鐘
716.77M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-2.07%
5天
-2.95%
1月
+6.79%
6月
+68.77%
今年開始到現在
+83.18%
1年
+91.09%
查看詳細走勢圖
TradingKey Regenxbio Inc股票評分
單位: USD 更新時間: 2025-12-26操作建議
Regenxbio Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名80/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價31.46。中期看，股價處於上升通道。近一個月，市場表現較強，技術面和基本面綜合得分較高，較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Regenxbio Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
13
分析師
買入
評級
31.462
目標均價
+137.62%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Regenxbio Inc亮點
亮點風險
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
業績增長期
公司處於發展階段，最新年度總收入83.33M美元
估值低估
公司最新PE估值-4.09，處於3年歷史低位
機構減倉
最新機構持股44.05M股，環比減少11.47%
PRFDX持倉
明星投資者PRFDX持倉，最新持倉18.92K股
Regenxbio Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Regenxbio Inc簡介
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
公司代碼RGNX
公司Regenxbio Inc
CEOSimpson (Curran M)
網址https://regenxbio.com/
常見問題
Regenxbio Inc(RGNX)的當前股價是多少？
Regenxbio Inc(RGNX)的當前股價是 14.160。
Regenxbio Inc 的股票代碼是什麼？
Regenxbio Inc的股票代碼是RGNX。
Regenxbio Inc股票的52週最高點是多少？
Regenxbio Inc股票的52週最高點是15.410。
Regenxbio Inc股票的52週最低點是多少？
Regenxbio Inc股票的52週最低點是5.035。
Regenxbio Inc的市值是多少？
Regenxbio Inc的市值是716.77M。
Regenxbio Inc的淨利潤是多少？
Regenxbio Inc的淨利潤為-227.10M。
現在Regenxbio Inc(RGNX)的股票是買入、持有還是賣出？
根據分析師評級，Regenxbio Inc(RGNX)的總體評級為買入，目標價格為31.462。
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是多少
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是-3.461。
相關品種
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
